{"id":"dexmedetomidine-hydrochloride-cycling","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Hypotension"},{"rate":"10-25","effect":"Bradycardia"},{"rate":"5-15","effect":"Hypertension (initial)"},{"rate":"5-10","effect":"Dry mouth"},{"rate":"5-10","effect":"Rebound hypertension on discontinuation"}]},"_chembl":{"chemblId":"CHEMBL2106195","moleculeType":"Small molecule","molecularWeight":"236.75"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexmedetomidine binds to alpha-2 adrenergic receptors in the locus coeruleus and other brain regions, reducing norepinephrine release and producing dose-dependent sedation, analgesia, and anxiolysis. The 'cycling' formulation refers to intermittent dosing protocols designed to maintain sedation while reducing tolerance and adverse effects associated with continuous infusion. It is commonly used in intensive care settings for sedation of mechanically ventilated patients.","oneSentence":"Dexmedetomidine hydrochloride is a selective alpha-2 adrenergic agonist that produces sedation and analgesia by activating alpha-2 receptors in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:35.968Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sedation of mechanically ventilated patients in intensive care units"},{"name":"Sedation and analgesia in perioperative settings"}]},"trialDetails":[{"nctId":"NCT05003102","phase":"PHASE4","title":"Dexmedetomidine Cycling and Sleep in the Pediatric ICU","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2023-02-20","conditions":"Critical Illness, Sedation Complication, Delirium","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Precedex"],"phase":"marketed","status":"active","brandName":"Dexmedetomidine Hydrochloride - Cycling","genericName":"Dexmedetomidine Hydrochloride - Cycling","companyName":"Vanderbilt University Medical Center","companyId":"vanderbilt-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexmedetomidine hydrochloride is a selective alpha-2 adrenergic agonist that produces sedation and analgesia by activating alpha-2 receptors in the central nervous system. Used for Sedation of mechanically ventilated patients in intensive care units, Sedation and analgesia in perioperative settings.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}